PSA vs REPL
PSA (PSA) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
PSA (PSA) common stock.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
REPL does not have a complete income-statement cache yet.
PSA currently screens at market cap $0. REPL currently screens at market cap $825.7M.
Not investment advice. Open the PSA and REPL stock pages for the full models.
Not investment advice.